Company profile
Bicara Therapeutics Inc.
NASDAQ:BCAXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Ficerafusp Alfa | phase1 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06788990 | phase2_3 | recruiting | 2025-01-28 | 2028-04-01 | Bicara Therapeutics | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
| NCT04429542 | phase1 | recruiting | 2020-06-01 | 2026-12-31 | Bicara Therapeutics | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors |
FDA applications (0)
No records yet.